Protease-Sensitive Inhibitory Activity of Cell-free Supernatant of Lactobacillus crispatus 156 Synergizes with Ciprofloxacin, Moxifloxacin and Streptomycin Against Pseudomonas aeruginosa: An In Vitro Study
- 285 Downloads
Ciprofloxacin and streptomycin are frequently prescribed for the treatment of medical conditions originating due to infection by Pseudomonas aeruginosa. However, fluoroquinolone administration has been linked to the outgrowth of Clostridium difficile pathogen, especially in immunocompromised patients. Secondly, frequent administration of antibiotics may lead to development of resistance in the pathogens. Thus, there is a need to explore innovative adjunct therapies to lower the therapeutic doses of the antibiotics. Herein, we evaluated the synergism, if any, between conventional antibiotics and the cell-free supernatant (CFS) of vaginal Lactobacillus crispatus 156 against P. aeruginosa MTCC 741. L. crispatus 156 was isolated from the human vaginal tract, and its CFS had broad-spectrum antimicrobial activity against various Gram-positive and Gram-negative pathogens, including P. aeruginosa. The inhibitory substance present in the CFS completely lost its activity after treatment with proteinases and was resistant to temperatures up to 80 °C and pH ranging from 2 to 6. The cumulative production of the inhibitory substance in CFS was studied, and it showed that the secretion of the inhibitory substance was initiated in middle log phase of growth and peaked in late log phase. Further, CFS synergized the activities of ciprofloxacin, moxifloxacin, and streptomycin as evaluated in terms of checkerboard titrations. It lowered the minimum inhibitory concentration (MIC) of ciprofloxacin by almost 30 times and MIC of both moxifloxacin and streptomycin by 8 times. Interestingly, pepsin treatment of CFS caused the complete abrogation of its synergistic effect with all the three antibiotics. Thus, from the study, it can be concluded that probiotic-based alternative therapeutic regimen can be designed for the treatment of P. aeruginosa infections.
KeywordsLactobacillus crispatus Probiotic Fluoroquinolones Pseudomonas aeruginosa Synergistic activity
This work was funded by a research grant to Dr. Sukhraj Kaur by the University Grants Commission (UGC; Vide F.No. 42-478/2013 (SR), dated: 22/03/2013), New Delhi, India. Ms. Preeti Sharma is grateful to UGC for the award of Junior Research Fellowship under the scheme University of Potential for Excellence, granted to Guru Nanak Dev University, Amritsar, India.
Conflict of Interest
Sukhraj Kaur and Preeti Sharma declares that they have no conflict of interest.
- 1.National Nosocomial Infections Surveillance system report (1999) Data summary from January 1990–May 1999. Am J Infect Control 2:520–532Google Scholar
- 8.Stapleton AE, Au-Yeung M, Hooton TM, Fredericks DN, Roberts PL, Czaja CA et al (2011) Randomized, placebo-controlled phase 2 clinical trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52:1212–1217CrossRefGoogle Scholar
- 11.Kim J, Rajagopal SN (2001) Antibacterial activities of Lactobacillus crispatus ATCC 33820 and Lactobacillus gasseri ATCC 33323. J Microbiol 39:146–148Google Scholar
- 14.Holt JG, Krieg NR, Sneath PH, Staley JT, Williams ST (1994) Bergeys manual of determinative bacteriology, 9th edn. Lippincott Williams and Wilkins, BaltimoreGoogle Scholar
- 15.Moore E, Arnscheidt A, Kuger A, Strompl C, Mau M (2004) Simplified protocols for the preparation of genomic DNA from bacterial cultures. In: Kowalchuk GA, de Bruijn FJ, Head IM, Van der Zijpp AJ, van Elsas JD (eds) Molecular microbial ecology manual, 2nd edn. Kluwer Academic Publishers, Netherland, pp 3–18Google Scholar
- 17.Geis A, Singh J, Teuber M (1983) Potential of lactic streptococci to produce bacteriocin. Appl Environ Microbiol 45:205–211Google Scholar
- 19.Bauer AW, Kirby MM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45:493–496Google Scholar
- 20.National Committee for clinical laboratory standards (2000) Performance standards for antimicrobial disk susceptibility tests, 7th edn. Approved standard M2-A7. NCCLS, WayneGoogle Scholar
- 23.Dicks LMT, Heunis TDJ, Staden DAV, Brand A, Noll KS, Chikindas ML (2011) Medical and personal care applications of bacteriocins produced by Lactic acid bacteria. In: Drider D, Rebuffat S (eds) Prokaryotic antimicrobial peptides: from genes to applications. Springer, New York, pp 391–421CrossRefGoogle Scholar
- 34.Drlica K, Zhao XK (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377–392Google Scholar